Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial statements or performance metrics.
Material Changes
The only material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On December 1, 2003, the GSK Trust transferred 8,858 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on December 2, 2003.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all employees or former employees are potential beneficiaries. Consequently, directors Dr. J-P Garnier and Mr. J D Coombe hold an interest in the shares held by the trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 8,858 shares.
- Confirm the specific impact of this transaction on the beneficial ownership of directors Dr. J-P Garnier and Mr. J D Coombe.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the recipients.